Asieris appoints Dr Badrinath Konety to Scientific Advisory Board

Dr Konety has more than 30 years of clinical research and medical practice experience in the field of genitourinary oncology

Asieris Pharmaceuticals, a global biopharma company specialising in discovering and developing innovative drugs for the treatment of genitourinary tumours and other related diseases, announced that Dr Badrinath Konety has joined Asieris’ Scientific Advisory Board as an advisor.


Dr Konety has more than 30 years of clinical research and medical practice experience in the field of genitourinary oncology. He is currently the President of Allina Health Cancer Institute and Chief System Research Officer. He is also a professor in the Department of Urology, Rush Medical College. Before that, he had served as Professor and Dougherty Family Chair in Uro-Oncology, and Chairman, Department of Urology, University of Minnesota. His clinical and hospital roles have seen him serve as CEO of the University of Minnesota Physicians and Dean of Rush Medical College. Dr Konety has held several leading positions and offices in professional organizations such as the Presidents of the Society of Academic Urologists and Société Internationale d’Urologie.

He has been an author and/or co-author of more than 300 publications and on the editorial board of several journals. He has served as Associate Editor of the Journal of Urology. He has received research funding from several organizations including NIH and the Dept of Defense. Dr Konety graduated with a medical degree from MS Ramaiah Medical College of Bangalore University, India and completed his MBA at the Katz Graduate School of Business at the University of Pittsburgh. He completed an American Foundation for Urologic Disease research fellowship and then trained as a Chief Clinical Fellow in Urology at Memorial Sloan Kettering Cancer Center. 

“We are honoured to have Dr Konety on our Scientific Advisory Board,” remarked Dr Kevin Pan, Founder and CEO, Asieris. “With his profound expertise in the global genitourinary field, we are confident that Dr Konety will play a critical role in helping Asieris define and optimize growth objectives and strategies to accelerate its innovation ambitions to become a global speciality biopharmaceutical company.”

“I’m impressed by Asieris’ global vision as well as its innovative pipeline powered by its competitive research and development engine,” Dr Konety stated. “I look forward to working with the management team to advance cutting-edge science to serve our patients worldwide.”


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button